TLR9 and neoplasm: CpG oligodeoxynucleotide (ODN), extensively investigated as an immune adjuvant [4], is recognized by toll-like receptor 9 (TLR9) and induces immune responses, during which effective presentation of tumor-specific antigen (TSA) to T lymphocytes is essential for subsequent activation of CTLs that ultimately eliminate tumor cells.